Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

Toplak, H.
The pharmacolocial management of obesity
AUST J CLIN ENDOCR M. 2016; 9(2): 43-45. [OPEN ACCESS]
Web of Science

Führende Autor*innen der Med Uni Graz: Toplak Hermann
Altmetrics:
Abstract:: Obesity is the quickest growing disease and a very central challenge for health systems worldwide. Epidemiological and intervention studies have confirmed the value of weight loss, especially in people with diabetes mellitus type 2, weight increases, even modest, on the contrary seem to be disadvantageous. The basis of therapy is always lifestyle modification, drug treatment and bariatric surgery can be used additionally. Since 2012 in the US four pharmacological drug options (Lorcaserin, Topiramat- Phentermin, Naltrexon-Bupropion and Liraglutid), in Europe only the latest two have been registered - following the same study results. We consider such products as permanent or interval-treatment, but perhaps best for weight maintenance such as following very low oder low calorie diets (VLCD, LCD).
Find related publications in this database (Keywords): Obesity therapy; Lorcaserin; Topiramat-Phentermin; Naltrexon-Bupropion; Liraglutid